

MD Anderson at the 2025 AACR Annual Meeting

MDAnderson.org/AACR

All times are listed in Central Time.

Friday, April 25		As of April 18
3-4:30 p.m.	ED27 - Advances in Gene and Cellular Therapy Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)	
3:30- 3:50 p.m.	Physical and biological approaches for gene and T cell delivery against solid tumors	Shulin Li, Ph.D.
3:50-4 p.m.	Discussion	
3-4:30 p.m.	MW03 - Statistical and Design Considerations for Dose Optimization Room S401 - McCormick Place South (Level 4)	
3-3:01 p.m.	Chair/Introduction	Ying Yuan, Ph.D.
3:31-3:51 p.m.	Using backfill for flexible and efficient dose optimization	
3:51-4 p.m.	Discussion	
4:45-6:15 p.m.	ED47 - The Microbiota and Cancer Prevention, Diagnosis, and Treatment Room S105 - McCormick Place South (Level 1)	
4:46-5:06 p.m.	Tumor-infiltrating microbes and their impact on the tumor microenvironment	Christopher Johnston, Ph.D.
5:06-5:15 p.m.	Discussion	
Saturday, April 26		
8-9:30 a.m.	ED52 - Innovative Approaches in TME Biology: From Profiling to Function Room S105 - McCormick Place South (Level 1)	
8:30-8:50 a.m.	Decoding the premalignant breast cancer microenvironment	Nicholas Navin, Ph.D.
8:50-9 a.m.	Discussion	
8-9:30 a.m.	MW01 - Integrating Computational Pathology, AI, and Spatial Multi-Omics in 2D and 3D Room S102 - McCormick Place South (Level 1)	
8-8:01 a.m.	Chair/Introduction	Linghua Wang, M.D., Ph.D.
8:31-8:51 a.m.	Precision mapping of tumor ecosystems via computational pathology and spatial multi-omics	
8:51-9 a.m.	Discussion	
12:30-2 p.m.	MW10 - Statistics Made Simple, Engaging, and Practical: A Primer for Non-Statisticians Room S405 - McCormick Place South (Level 4)	
12:30-12:31 p.m.	Chair/Introduction	Jack Lee, Ph.D., D.D.S.
12:31-12:51 p.m.	Enhancing quantitative reasoning through statistical thinking and exploratory data analysis	
12:51-1 p.m.	Discussion	
2:30-4 p.m.	ED60 - Extracellular Vesicles and Exosomes: Basic and Applied Biology Informing Translational Opportunities Room S405 - McCormick Place South (Level 4)	
2:30-2:31 p.m.	Chair/Introduction	Raghu Kalluri, M.D., Ph.D.
2:31-2:51 p.m.	To be announced	
3:31-4 p.m.	Panel Discussion	
2:30-4 p.m.	MW07 - Clinical Trial Design Workshop: Complexities of Current Phase I Clinical Trials Room S102 - McCormick Place South (Level 1)	
2:30-2:31 p.m.	Chair/Introduction	David Hong, M.D.
2:31-2:51 p.m.	The challenges now and ahead in Phase I	
2:51-2:56 p.m.	Discussion	
2:30-4 p.m.	MW09 - Reading the Tumor Tea Leaves: Integrating Novel Tumor Biomarkers in Epidemiological Research Room S103 - McCormick Place South (Level 1)	

2:30-2:31 p.m.	Chair/Introduction	Paul Scheet, Ph.D.
2:31-2:51 p.m.	Phenotyping the genotype: The genetics and risk of acquired chromosomal alterations	
2:51-3 p.m.	Discussion	
Sunday, April 27		
Noon-12:45 p.m.	LE19 - Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)	
12:05-12:10 p.m.	Chair remarks	Giulio Draetta, M.D., Ph.D.
12:30-1 p.m.	Meet the Experts: Interventions for Adverse Effects of EGFR Inhibitors Anisha Patel, M.D.	MD Anderson Booth 2527
1-3 p.m.	CTPL01 - Advances in Immunotherapy Arie Crown Theater - McCormick Lakeside Center (Level 2)	
2:15-2:25 p.m.	Discussant	Michael Overman, M.D.
2:30-2:45 p.m.	CT004 - KEYLYNK-007: Tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers	Timothy Yap, M.B.B.S., Ph.D.
2-2:30 p.m.	Meet the Experts: Clinical Trials at MD Anderson Christopher Flowers, M.D., and Jennifer Litton, M.D.	MD Anderson Booth 2527
2-5 p.m.	Posters South Hall A See the full listing of posters from MD Anderson starting on page 7.	
2:30-3 p.m.	Meet the Experts: Student Opportunities at MD Anderson Adam Grippin, M.D., Ph.D., Jillian Gunther, M.D., Ph.D., Marites Melancon, Ph.D., and Vickie Shannon, M.D.	MD Anderson Booth 2527
3-3:30 p.m.	Meet the Experts: Spatialomics—Mapping the Tumor Ecosystem Anirban Maitra, M.B.B.S., Linghua Wang, M.D, Ph.D., and Di Zhao, Ph.D.	
	Meet the Experts: Cancer Vaccines—The Current Landscape Eduardo Vilar-Sanchez, M.D., Ph.D., and Jason Willis, M.D., Ph.D.	
3-5 p.m.	MS.MCB10.01 - microRNAs and Other Noncoding RNAs Room E351 - McCormick Lakeside Center (Level 3)	
3:05-3:20 p.m.	1186 - microRNA-targeted small molecule inhibitors in metastatic cancers	Maria-Ancuta Jurj, Ph.D.
3-5 p.m.	CTMS01 - ADCs and Immunooncology-focused Biological Approaches Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)	
4:05-4:15 p.m.	CT012 - Personalized neoantigen vaccine with or without pembrolizumab in patients with microsatellite-stable metastatic colorectal cancer	Daniel Haldar, M.D.
3-5 p.m.	MS.CL10.01 - Real-World Evidence: Clinico-genomics, Clinical Informatics, and Data Science Room E450 A - McCormick Lakeside Center (Level 4)	
4:05-4:20 p.m.	1155 - Highly CNS-penetrant tyrosine kinase inhibitors improve leptomeningeal overall survival in NSCLC patients with leptomeningeal disease	Xiuning Le, M.D., Ph.D.
3:30-5:30 p.m.	CTPL02 - New Frontiers in Precision Oncology Arie Crown Theater - McCormick Lakeside Center (Level 2)	
3:30-3:45 p.m.	CT016 - First-in-human (FIH) Phase I trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and/or mismatch repair deficient (dMMR) advanced solid tumors	Timothy Yap, M.B.B.S., Ph.D.
4:30-4:45 p.m.	CT018 - A double-blind placebo-controlled randomized Phase II clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies	Anisha Patel, M.D.
4:30-5:15 p.m.	LE15 - AACR-Princess Takamatsu Memorial Lectureship Room S102 - McCormick Place South (Level 1)	
4:40-5:15 p.m.	The age of cancer: Insights and interception	Ronald DePinho, M.D.
6:30-8:30 p.m.	TM02 - Acquired Resistance to Immunotherapies: A Cancer Immunology Working Group Town Hall and Networking Meeting Room S105 - McCormick Place South (Level 1)	
7:25-7:40	Invited speaker	Pavan Bachireddy, M.D.

6:30-8:30 p.m.	TM08 - The Weight of the Matter: Obesity Drugs, Cancer, and Population Health- A Population Sciences Working Group Town Hall Room S102 - McCormick Place South (Level 1)	
7-7:10 p.m.	Chair	Paul Scheet, Ph.D.
7:25-8 p.m.	Panel Discussion	Jasmine Singh Sukumar, M.D.
6:30-8:30 p.m.	TM09 - Bugs and Rads: Tumor Microbiome and Radiation Response/Toxicity- A Radiation Science and Medicine Working Group Town Hall Room S101 - McCormick Place South (Level 1)	
	Speaker	Lauren Colbert, M.D.
Monday, April 28		
9 a.m.-noon	Posters South Hall A	
	See the full listing of posters from MD Anderson starting on page 7.	
10:15 - 11:45 a.m.	AT03 - Digital Twins in Cancer: New Era of Personalized Medicine Room E451 - McCormick Lakeside Center (Level 4)	
10:15-10:17 a.m.	Chair Introduction	Caroline Chung, M.D.
10:17-10:35 a.m.	Enabling digital twins in oncology: What will it take?	
10:35-10:38 a.m.	Discussion	
10:15-11:45 a.m.	ASD04 - Optimizing Outcomes in AYA Cancer patients Room E352 - McCormick Lakeside Center (Level 3)	
10:45-11:05 a.m.	Collaborating to increase clinical trial participation in AYA cancer patients	Michael Roth, M.D.
11:05-11:10 a.m.	Discussion	
10:15-11:45 a.m.	SY09 - Mechanisms and Targeting of Neuroendocrine Dysregulation and Inflammation in Cancer Cachexia Room E351 - McCormick Lakeside Center (Level 3)	
11:10-11:30 a.m.	SY09-01 - Targeting the vagal gut-brain axis: A new approach to combat cachexia	Xiling Shen, Ph.D.
11:30-11:35 a.m.	Discussion	
10:15-11:45 a.m.	SY48 - Targeting Innate Immune Cell Subsets Room E450 A - McCormick Lakeside Center (Level 4)	
11:10-11:30 a.m.	Engineering NK cells for cancer treatment: From bench to bedside	Katy Rezvani, M.D., Ph.D.
11:30-11:35 a.m.	Discussion	
10:15 a.m.-12:15 p.m.	CTPL03 - Therapeutic Advances in Non-Small Cell Lung Cancer Arie Crown Theater - McCormick Lakeside Center (Level 2)	
10:15-10:30 a.m.	CT050 - Zongertinib in patients with pretreated HER2-mutant advanced NSCLC: Beamion LUNG-1	John Heymach, M.D., Ph.D.
12-12:30 p.m.	Meet the Experts: Institute for Cell Therapy Discovery & Innovation Cathy Dumbrava, M.D., and Katy Rezvani, M.D., Ph.D.	MD Anderson Booth 2527
12-1 p.m.	Meet the Experts: Career Opportunities at MD Anderson Giulio Draetta, M.D., Ph.D.	
1-1:30 p.m.	Meet the Experts: Cancer Neuroscience—An Emerging Integrative Field Jian Hu, M.D.	
2-2:30 p.m.	Meet the Experts: Genotyping—A New Frontier in Early Cancer Detection and Risk Profiling Paul Scheet, M.D.	
2-3 p.m.	MG07 - Meet the new Editor-in-Chief of Clinical Cancer Research AACR Publications Booth 2615 - South Halls A1-2	
	Editor-in-Chief of Clinical Cancer Research	Timothy Yap, M.B.B.S., Ph.D.
2-5 p.m.	Posters South Hall A	
	See the full listing of posters from MD Anderson starting on page 7.	
2:30-4 p.m.	SS07 - Advances in the Detection and Treatment of Gastrointestinal Cancers: SU2C Open Scientific Session Room E353 C - McCormick Lakeside Center (Level 3)	
3:16-3:38 p.m.	Therapeutic implications of selective bacterial colonization of colorectal cancer	Florencia McAllister, M.D.
2:30-4:15 p.m.	MS.MD01.01 - Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases Room E350 - McCormick Lakeside Center (Level 3)	

3:20-3:35 p.m.	3746 - Genomic landscape in metaplastic breast cancer: Results from the AACR GENIE Database	Blessie Nelson, M.B.B.S.
2:30-4:30 p.m.	MS.TB04.01 - Cancer Models: Mechanisms and Therapies Room S401 - McCormick Place South (Level 4)	
3:50-4:05 p.m.	3824 - Investigating the role of allelic imbalance in pancreatic cancer aggressiveness, survival, and therapeutic resistance	Enrico Gurreri
2:30-4:30 p.m.	CTMS02 - Aiming for Cure: Adjuvant and Neoadjuvant Approaches Room S406 (Vista Ballroom) - McCormick Place South (Level 4)	
4:05-4:15 p.m.	CT132 - Phase II trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker	Chad Tang, M.D.
4:15-4:20 p.m.	Discussion	
2:30-4:30 p.m.	MS.CL01.02 - Liquid Biopsy: Circulating Nucleic Acids Room S105 - McCormick Place South (Level 1)	
4:05-4:20 p.m.	3776 - Association of baseline ctDNA EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinib versus osimertinib in EGFR mutant non-small cell lung cancer	Simon Heeke, Ph.D.
2:30-4:30 p.m.	MS.MCB09.01 - Metabolic Frontiers in Cancer: Amino Acids, Nutrient Dependencies, and Therapeutic Opportunities Room E450 B - McCormick Lakeside Center (Level 4)	
	Chair	Boyi Gan, Ph.D.
4:20-4:30 p.m.	Closing Remarks	
3-3:45 p.m.	LE14 - AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship Room E351 - McCormick Lakeside Center (Level 3)	
3:10-3:45 p.m.	Addressing disparities in lymphoma outcomes	Christopher Flowers, M.D.
4-4:30 p.m.	Meet the Experts: Accelerating Drug Discovery with AI Bissan Al-Lazikani, Ph.D., and Tim Heffernan, Ph.D.	MD Anderson Booth 2527
5-6:30 p.m.	FO08 - Significance, Innovation, and Challenges of Biostatistics in Preclinical Studies, Clinical Trials, and Beyond Room E353 C - McCormick Lakeside Center (Level 3)	
5-5:05 p.m.	Chair/Introduction	Jack Lee, M.D., D.D.S.
5:05-5:25 p.m.	Foundation of biostatistics in preclinical studies	
5:30-6:15 p.m.	LE04 - AACR Award for Outstanding Achievement in Basic Cancer Research Room E351 - McCormick Lakeside Center (Level 3)	
5:35-6:15 p.m.	Fill the gap between big cancer data and cancer medicine	Han Liang, Ph.D.
6:30-8:30 p.m.	TM03 - Biomarker Discovery, Validation, and Clinical Implementation for Cancer Prevention: Success Stories and Lessons Learned— A Cancer Prevention Working Group Town Hall Room S102 - McCormick Place South (Level 1)	
7:10-7:20 p.m.	25 Years of Cancer Biomarker Research at the Early Detection Research Network (EDRN): A Presentation on Behalf of the EDRN	Anirban Maitra, M.B.B.S.
Tuesday, April 29		
9 a.m.-noon	Posters South Hall A	
	See the full listing of posters from MD Anderson starting on page 7.	
10:15-11:45 a.m.	AED02 - Opportunities in Cancer Early Detection using Next Generation Liquid Biopsies S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)	
10:16-10:36 a.m.	Circulating biomarkers for cancer risk assessment and early detection	Sam Hanash, M.D., Ph.D.
10:15-11:45 a.m.	AT01 - Reality Check: AI in Drug Discovery Room S406 (Vista Ballroom) - McCormick Place South (Level 4)	
10:15-10:16 a.m.	Chair/Introduction	Bissan Al-Lazikani, Ph.D.
11:07-11:27 a.m.	From and to the patient: Forward and reverse transition in drug discovery	
10:15 a.m.-12:15 p.m.	CTPL04 - Biologics and T-cell Engagers Arie Crown Theater - McCormick Lakeside Center (Level 2)	
10:30-10:30 a.m.	Discussant	Sangeeta Goswami, M.D., Ph.D.

11:45 a.m.-noon	CT206 - ICAM-1 directed chimeric antigen receptor (CAR) T cells (AIC100) in patients with advanced thyroid cancers: Clinical and translational data from the Phase I dose escalation study	Samer Srour, M.B.Ch.B.
12-12:30 p.m.	Meet the Experts: Functional Proteomics—Revealing the Role of Protein in Tumor Development Yiling Lu, M.D.	MD Anderson Booth 2527
12:30-2 p.m.	ADT05 - Bispecifics: The Case for Duality S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)	
12:35-12:55 p.m.	Preclinical development of bispecific antibodies: Opportunities and challenges	Tim Heffernan, Ph.D.
12:55-1 p.m.	Discussion	
12:30-2 p.m.	AT04 - Integrating Multi-Omics and Spatial Technologies for Discovery and Prediction Room S406 (Vista Ballroom) - McCormick Place South (Level 4)	
12:50-1:10 p.m.	Single-cell spatial multi-omics for mapping cell organization, interactions, and functional niches	Linghua Wang, M.D., Ph.D.
1:10-1:30 p.m.	Decipher actionable tumor suppressor defects for personalized cancer medicine	Di Zhao, Ph.D.
1-2 p.m.	Meet the Experts: The Postdoctoral Experience at MD Anderson Safia Essien, Ph.D., Jian Hu, M.D., Aria Vaishnavi, Ph.D., and Ankita Paul, Ph.D.	MD Anderson Booth 2527
2-2:30 p.m.	Meet the Experts: The Microbiome and Cancer Jennifer McQuade, M.D.	
2:30-3 p.m.	Meet the Experts: Synthetic Lethality and DDR Inhibitor Clinical Trials Timothy Yap, M.D., Ph.D.	
2:30-4:15 p.m.	MS.CL08.01 - Targeted Therapies and Combinations Room E451 - McCormick Lakeside Center (Level 4)	
2:35-2:50 p.m.	6367 - CHD1 loss hijacks SREBP2-mediated cholesterol biosynthesis to fuel SPOP-deficient prostate cancer and confers resistance to castration therapy	Feiyu Chen, Ph.D.
2:30-4:30 p.m.	MS.IM01.01 - Adoptive Cell Therapies Arie Crown Theater - McCormick Lakeside Center (Level 2)	
2:35-2:50 p.m.	6396 - CREM is a regulatory checkpoint of CAR and IL-15 signaling in NK cells	Hind Rafei M.D.
2:30-4:30 p.m.	MS.TB10.01 - The Local and Systemic Tumor Microenvironment in Cancer Progression Room S401 - McCormick Place South (Level 4)	
4:05-4:20 p.m.	6436 - Metabolic masquerade: glutamine's role in ovarian cancer dynamics	Sammy Ferri-Borgogno, Ph.D.
2:30-4:30 p.m.	MS.PR01.01 - Hot Topics in Cancer Prevention: Development of Multi-Cancer Early Detection Tests, Assessment of the Immune Environment, Targets for Cancer Prevention, and Cancer Interception Trials Room S402 - McCormick Place South (Level 4)	
2:50-3:05 p.m.	6424 - Harnessing circulating neoantigen-specific T cells for immune surveillance and cancer prevention in Lynch syndrome	Fahriye Duzagac, Ph.D.
3:35-3:50 p.m.	6427 - NGS-209 off-the-shelf neoantigen immunotherapy induces robust neoantigen T cell response with the potential to intercept cancer in Lynch syndrome carriers	Jason Willis, M.D., Ph.D.
2:30-4:30 p.m.	MS.MCB08.01 - Multi-omic Integration for Cancer Evolution and Therapy Room E352 - McCormick Lakeside Center (Level 3)	
3:35-3:50 p.m.	6438 - Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy	Yun Yan
2:30-4:40 p.m.	CTMS03 - Innovative Approaches to Key Molecular Targets Room S406 (Vista Ballroom) - McCormick Place South (Level 4)	
2:30-2:35 p.m.	Chair/Introduction	Jordi Rodon Ahnert, M.D., Ph.D.
3:20-3:30 p.m.	CT265 - KRAS ^{G12D} targeting using engineered exosomes in pancreatic cancer: Results from the iEXPLORE phase I trial	Valerie LeBleu, M.D., Ph.D.
3:30-3:35 p.m.	Discussion	
2:30-4:30 p.m.	MS.ET03.01 - Experimental Therapeutics: Drug Resistance Room E450 B - McCormick Lakeside Center (Level 4)	

3:20-3:35 p.m.	6384 - CD24 promotes development of <i>KRAS</i> -mutant lung adenocarcinoma and response to <i>KRAS</i> -targeted therapy	Zahraa Rahal, M.D.
3-3:30 p.m.	Meet the Experts: The Next Chapter in Cell Therapy Discoveries Samer Srour, M.B.Ch.B.	MD Anderson Booth 2527
1:30-5 p.m.	Posters South Hall A See the full listing of posters from MD Anderson starting on page 7.	
3-3:45	LE10 - AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention Room E353 C - McCormick Lakeside Center (Level 3)	
3-3:45 p.m.	Chair Remarks	Paul Scheet, Ph.D.
3-4 p.m.	ESP8A - Identification of Novel Blood-based Signatures of Disease and Therapeutic Response Using High-sensitivity NULISA Protein Assays Spotlight Theater A - South Hall A	
	Identification of novel blood-based signatures of disease and therapeutic response using high-sensitivity NULISA protein assays	Hussein Abbas, M.D., Ph.D.
		Adam Grippin, M.D., Ph.D.
5-6:30 p.m.	FO07 - Testing Diet with the Rigor of Drug: Dietary Interventions to Improve Cancer Treatment Outcomes Room E451 - McCormick Lakeside Center (Level 3)	
5-5:01 p.m.	Chair/Introduction	Jennifer McQuade, M.D.
5:05-5:15 p.m.	Considerations for dietary interventions in active cancer populations: Optimizing trial design	
5-6:30 p.m.	SS04 - Bringing Science to the Clinic: Overcoming Hurdles for Therapeutic Translation Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)	
5-5:01 p.m.	Chair/Introduction	Timothy Yap, M.B.B.S., Ph.D.
5:14-5:26 p.m.	Synthetic lethal therapeutic and biomarker strategies: Progress, pitfalls, and promise in novel clinical translation	
Wednesday, April 30		
9 a.m.-noon	Posters South Hall A See the full listing of posters from MD Anderson starting on page 7.	
10:15-11:45 a.m.	SY46 - Intratumoral Microbiota and Microbiota-Derived Metabolome: Friend or Foe Room S105 - McCormick Place South (Level 1)	
10:20-10:40 a.m.	To be announced	Floencia McAllister, M.D.
10:40-10:45	Discussion	

Posters South Hall A	
Sunday, April 27	
2-5 p.m.	
LBPO.ET01 - Late-Breaking Research: Experimental and Molecular Therapeutics 1 Section 50	
LB020 (Poster Board 20) - Role of acetylcholine in glioblastoma pathophysiology: Emerging insights	A. Gargapati
PO.BCS01.04 - Database Resources Section 46	
1061 (Poster Board 1) - Post-doctoral fellow	K. <u>Hsieh</u>
PO.BCS01.15 - Tumor Subtypes and Biomarker Discovery Section 47	
1095 (Poster Board 2) - Machine learning models predict tumor-specific total mRNA expression associated with clinical outcomes across 14 cancer types	A. Paul
1101 (Poster Board 8) - A novel machine learning classifier for SCLC transcriptional subtypes	M. Gay
PO.CL01.18. Spatial Proteomics and Transcriptomics 1 Section 32	
759 (Poster Board 11) - Spatial transcriptomics identifies unique tumor and microenvironment pathomic programs that are associated with the lung premalignancy and adenocarcinoma continuum	Y. Dai
763 (Poster Board 15) - Multimodal spatial-omics atlas of lung premalignancy and adenocarcinoma reveals tumor initiating interplay between alveolar progenitors and inflammation	F. Peng
PO.CL06.02 - Combination Immunotherapies Section 28	
646 (Poster Board 12) - Unravelling the mechanisms of resistance and hyperprogression of renal medullary carcinoma to immune checkpoint therapy	J. Qian
660 (Poster Board 26) - Investigating the mechanism of the abscopal effect in combined IRE and anti-PD-1 therapy against PDAC	C. Li
PO.CL08.01 - Targeted Therapies and Combinations 1 Section 34	
825 (Poster Board 13) - Correlation of clinical and biomarker data in FGFR inhibitor failed metastatic cholangiocarcinoma patients with tumor response to tinengotinib	S. Piha-Paul
PO.CL12.01 - Survivorship Research and Supportive Care Section 33	
809 (Poster Board 28) - Food choices of patients with advanced cancer at start of early-phase combination trials with immune checkpoint blockade	G. George
PO.ET02.05 - Repurposing New and Existing Drugs for Cancer Treatment Section 23	
516 (Poster Board 10) - SOX4 dictates gastric cancer progression by modulating the tumor immune microenvironment	G. Zou
517 (Poster Board 11) - YAP-TEAD-mediated tumor suppression and immune modulation of gastric adenocarcinoma by HSP90 inhibition	
PO.ET03.03 - Reversal of Drug Resistance 1 Section 24	
553 (Poster Board 15) - Drp1 knockdown impairs mitophagy and sensitizes AML cells to venetoclax by inducing apoptosis	P. Sharma
PO.ET05.01 - Cell Cycle Effects of Anticancer Drugs Section 17	
358 (Poster Board 2) - INK4A/B as predictive biomarkers for enhanced efficacy of dual WEE1 and PKMYT1 inhibition in CDK4/6 inhibitor-resistant breast cancer	M.K. Chen
359 (Poster Board 3) - Rb loss-related DNA damage repair deficiency mediates the synthetically lethal effect of ATR/PKMYT1 co-inhibition in TNBC and CDK4/6i-resistant ER+ breast cancer	X. Jiang
63 (Poster Board 7) - Exploiting Rb-deficiency: Dual inhibition of TRIP13 and Aurora A as a path to mitotic catastrophe	L. Yapindi
366 (Poster Board 10) - CDK7 inhibition as a synthetic lethal strategy in Rb-deficient ER+/HER2-breast cancer and sarcoma cells resistant to CDK4/6 inhibitors	R. Esmaeili
PO.ET09.02 - Epigenetic Targets Section 20	
444 (Poster Board 5) - ASXL1 mutations in AML are associated with a distinct epigenetic state that results in vulnerabilities to epigenetic-targeted agents	C. Mill
447 (Poster Board 8) - Preclinical development and characterization of IACS-16559, a dual bromodomain inhibitor of CBP/EP300, and its potential in AML subtypes	C. Zanca

451 (Poster Board 12) - Superior preclinical efficacy of BRG1/BRM inhibitor combined with BET inhibitor or decitabine against MECOM-rearranged AML 9	W. Fiskus
PO.IM02.01 - Tumor-induced Immune Suppression: Intrinsic and Extrinsic Factors Section 38	
905 (Poster Board 6) - SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy	Y. Lissanu
PO.MCB03.02 - Cell Signaling and Tumor-Stroma Cell Interactions Section 8	
198 (Poster Board 16) - Ovary to the moon: proximity ligation assay catches APoE in the act	S. Ferri-Borgogno
PO.MCB09.04 - Metabolomics Section 12	
287 (Poster Board 9) - Circulating metabolites associated with response to immune checkpoint blockade in melanoma	N. Dizman
PO.MCB11.01 - Mechanisms of Oncogenesis and Tumor Suppression Section 11	
268 (Poster Board 12) - Ryanodine receptor-1 upregulation alters organellar calcium signaling, modulates gene expression and contributes to ovarian cancer development	C. Au-Yeung
273 (Poster Board 17) - Decipher actionable tumor suppressor defects in prostate cancer for precision medicine	D. Zhao
PO.MD01.01 - AACR Project GENIE Use Cases Section 48	
1121 (Poster Board 7) - Pan-cancer prevalence of unusual MTAP alterations: data from the AACR GENIE database	M. Gouda
PO.TB10.05 - Where's Waldo: Spatial Complexity of the Tumor Microenvironment 1 Section 7	
166 (Poster Board 17) - Spatial subtypes and cellular interactions of cancer-associated fibroblasts revealed by single-cell spatial omics	Y. Liu
PO.TB07.01 - Stem Cells, Development, and Cancer Section 5	
120 (Poster Board 10) - Developing a novel intra-portal stem cell hydrogel carrier system for enhancing liver remnant hypertrophy and improving surgical eligibility for hepatocellular carcinoma: preclinical assessment in a murine model of portal vein blockade	D. K. Bolinas
PO.TB03.04 - Molecular Regulation of Metastasis Section 4	
103 (Poster Board 26) - Syndecan-1 Is a key mediator of entosis and cellular competition in pancreatic cancer	K. Li
PO.TB04.02 - Human and PDX Models 1 Section 2	
37 (Poster Board 16) - Characterization of cervical cancer patient derived organoid	R. Wang
Monday, April 28	
9:00 a.m.-noon	
LBPO.TB02 - Late-Breaking Research: Tumor Biology 2 Section 54	
LB174 (Poster Board 14) - REST-USP37 axis controls GLI1 levels in sonic hedgehog medulloblastoma cells	A. Singh
PO.BCS01.01 - Artificial Intelligence for Digital Pathology and Spatial Molecular Technologies Section 45	
2426 (Poster Board 11) - TMEseg: Connecting histopathology with spatial transcriptomics through tumor microenvironment segmentation for lung cancer	X. Pan
2428 (Poster Board 13) - Artificial intelligence for predicting spatial proteomics using high-plex digital spatial profiling in carcinomas	Y. Shokrollahi
PO.BCS01.05 - Quantitative Methods and Pipelines Section 47	
2480 (Poster Board 1) - DeMixT 2.0: A deconvolution framework for sparse sequencing data using embedded negative binomial distribution	H. Yan
PO.BCS02.01 - Digital Pathology Section 46	
2450 (Poster Board 2) - Slide-level foundation models exhibit effective diagnostic and prognostic performance in H&E-stained histopathology	S. Ranjbar
PO.CH02.01 - Proteomic Signatures in Cancer Section 26	
1884 (Poster Board 14) - Pancreatic cyst fluid proteins distinguish dysplasia grade of intraductal papillary mucinous neoplasm	J. Zhang
PO.CL01.13 - Diagnostic Biomarkers 3: Early Detection Biomarkers Section 27	

1913 (Poster Board 13) - Cystic fluid acetylated polyamines predict risk of malignancy of intraductal papillary mucinous neoplasms of the pancreas	R. Ballarò
PO.CL01.15 - Metastasis Biomarkers / Prognostic Biomarkers 1 Section 30	
2002 (Poster Board 4) - A blood-based microbial metabolites signature for associated with metastatic duodenopancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1	R. Ballarò
PO.CL06.04 - Therapeutic Antibodies, Including Engineered Antibodies 1 Section 34	
2143 (Poster Board 29) - Sequential anti-folate (pemetrexed) and anti-PD-L1 (avelumab) combination therapy in patients with previously treated MTAP-deficient advanced urothelial cancer: Clinical outcomes and immune correlative analyses	X. Yan
PO.CT01.03 - Phase 0 and Phase I Clinical Trials Section 49	
CT024 (Poster Board 3) - $\gamma\delta$ 2 T-cell ($\gamma\delta$ TC) activation and azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) acute myeloid leukemia (AML) induces high rates of complete remission (CR): Preliminary efficacy, safety, pharmacodynamics (PD) and dose selection of ICT01 in the phase 1 study EVICTION	A. Maiti
CT046 (Poster Board 25) - Clinical and translational study of the TGF- β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial	C. Torrado
PO.ET02.03 - Drug Combination Strategies for Cancer Treatment Section 19	
1683 (Poster Board 14) - Combining annamycin, a non-cardiotoxic potent topo II poison, with azacitidine, cytarabine, gemcitabine, ifosfamide, trabectedin, or vincristine to synergize anticancer effects and identify potential clinical applications	W. Priebe
1689 (Poster Board 20) - Targeting PARP to enhance sensitivity to MEK inhibitors in low-grade serous ovarian cancer	G. Bildik
PO.ET03.06 - Drug Resistance in Molecular Targeted Therapies 2 Section 20	
1716 (Poster Board 17) - Acquired cell adhesion molecule 1 (CADM1) ADC resistance model for optimizing payload efficacy and toxicity in osteosarcoma preclinical testing	Z. Zhang
PO.ET08.02 - Radiation Treatment Combinations for Tumors, Normal Tissue Section 24	
1832 (Poster Board 18) - Identifying GSK3b inhibitor as a radiation induced type I interferon stimulator in lung cancer	C. Braun
PO.ET09.01 - Kinase and Phosphatase Inhibitors 1 Section 21	
1746 (Poster Board 21) - FGFR3 inhibition is a highly effective therapy in MTAP-deficient, FGFR3 altered urothelial carcinoma	Y. Chu
PO.ET09.10 - Degradable and Glues 2 Section 18	
1663 (Poster Board 23) - Discovery of novel, potent and orally bioavailable SMARCA2 PROTACs with synergistic anti-tumor activity in combination with KRAS G12C inhibitors	Y. Lissanu
PO.IM02.02 - Microbiome, Inflammation, and Cancer Section 37	
2225 (Poster Board 22) - Diet with high soluble fiber induces favorable gut microbiota and metabolomic profiles, increases anti-tumor immunity, and suppresses lung cancer progression	M. Sharma
PO.MCB05.02 - Genome Maintenance: Mechanisms and Novel Therapeutics Section 12	
1481 (Poster Board 17) - Targeting DNA damage responsive pathways in cancer therapy	J. Chen
PO.MCB07.02 - Gene Regulation and Transcription Factors 2 Section 10	
1404 (Poster Board 1) - Coactivator-associated arginine methyltransferase 1 regulates the transcriptional coactivator function of glioblastoma tumor suppressor Quaking	K. Lu
PO.MCB07.03 - Gene Regulation and Transcription Factors 3 Section 11	
1435 (Poster Board 4) - ATRX loss blocks the differentiation of mesenchymal stem cells and advances undifferentiated sarcoma development	Y. Cai
PO.PR01.05 - Biology of Precancers, Development of Early Detection Methods and Biomarkers, and Cancer Interception Section 42	
2327 (Poster Board 3) - Boosting cancer vaccine efficacy with Vitamin E for immunoprevention of ER- breast cancer	Y. Xiao

2331 (Poster Board 7) - WNT/ β -catenin modulation by activation of the farnesoid X receptor for interception of familial adenomatous polyposis-associated colorectal cancer	A. Martel-Martel
PO.PR02.02 - Biomarkers and Molecular Targets for Prevention Section 43	
2360 (Poster Board 3) - Targeting of microRNA let-7b-5p-mediated aberrant AR signaling inhibits the growth and proliferation of preneoplastic and preinvasive stages of triple-negative breast cancer	L. Cando
2366 (Poster Board 9) - Dynamic crosstalk between endothelial and epithelial cells drives tumor progression in lung adenocarcinoma	H. Chen
PO.TB06.01 - Radiation Sciences 1 Section 6	
1341 (Poster Board 14) - A novel ATR inhibitor combined with radiation sensitizes an immunologically cold tumor to immunotherapy	G. Sawakuchi
PO.TB09.01 - Cancer Evolution In Response to Therapy Section 2	
1263 (Poster Board 24) - Reconstructing small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA	B. Morris
PO.TB10.15 - Uncovering How Secreted Factors Sculpt the Tumor Microenvironment Section 7	
1360 (Poster Board 15) - Neutrophil extracellular traps establish the pre-metastatic niche in the omentum by expanding innate-like B cells that express IL-10	W. Lee
1363 (Poster Board 18) - Cancer cell-derived exosomal microRNAs enhance immunosurveillance in long-term survivors of high-grade serous ovarian cancer	C. Au Yeung
1370 (Poster Board 25) - Antibodies derived from patient tumors augment response to immune checkpoint blockade in cancer	M. Chelvanambi
2-5 p.m.	
PO.BCS01.02 - Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery Section 45	
3651 (Poster Board 13) - AI-derived immune cell knowledge graphs to advance immunotherapy	S. He
3658 (Poster Board 20) - LINE1 ORF1P is a druggable target for early onset colorectal cancer and cancer prevention	D. Zhao
PO.BCS02.02 - Convergence Science Diagnostic and Predictive Approaches Section 46	
3673 (Poster Board 2) - Identifying druggable target in medulloblastoma	D. Mao
PO.CL06.12 - Modifiers of the Tumor Microenvironment	
3279 (Poster Board 11) - Smoking burden is associated with immunotherapy resistance in extensive stage small cell lung cancer	K. Concannon
PO.CT01.01 - First-in-Human Phase I Clinical Trials 1 Section 49	
CT064 (Poster Board 9) - Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA \times CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)	B. Siddiqui
PO.CTP01.01 - Phase I Clinical Trials in Progress 1 Section 51	
CT109 (Poster Board 4) - A first-in-human Phase I study of LY4050784, an oral, potent, and selective SMARCA2 inhibitor, in patients with advanced solid tumors with SMARCA4 alterations (Trial in Progress)	T. Yap
PO.ET01.03 - Growth Factor Receptors and Other Surface Antigens as Targets for Therapy 1 Section 17	
2928 (Poster Board 2) - Combination surface targeting strategies in relapsed small cell lung cancer (SCLC) to overcome intratumoral heterogeneity associated with treatment resistance	A. Stewart
2929 (Poster Board 3) - LX-101, a novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent anti-tumor activity in Ewing sarcoma animal models and desmoplastic small round cell tumor	J. Ludwig
2931 (Poster Board 5) - AXL-directed surface targeting approaches in recalcitrant pulmonary high-grade neuroendocrine carcinomas	K. Ramkumar
PO.ET02.09 - Therapeutic Approaches to Attack the Tumor Microenvironment Section 24	
3141 (Poster Board 26) - Development and comprehensive preclinical evaluation of dual-drug polymeric micelles ONP-001 for PDAC and HCC	C. Li

PO.ET05.03 - The Microenvironment in Therapeutic Response Section 23	
3094 (Poster Board 2) - Aurora-A inhibition sensitizes HPV-driven cancers to anti-CTLA-4 immunotherapy by modulating the tumor immune microenvironment	S. Ghosh
PO.IM01.12 - Local Treatments, Novel Tools, and Delivery Systems to Manipulate Tumor Immunity Section 37	
3473 (Poster Board 12) - iPS-derived MSC secreting IL7 and IL15 exert immune mediated anti-tumor activities	M. Andreeff
3481 (Poster Board 20) - Transarterial embolization for HCC: how embolic agents shape tumor immunity and systemic responses	A. Cor
PO.IM01.18 - Vaccines, In Situ Vaccines, and Vaccine Combinations Section 39	
3548 (Poster Board 24) - Systemic antitumor immunity stimulated by intratumoral CD40 agonist in combination with PD1 therapy in immune-cold melanoma	B. Pazdrak
PO.IM02.03 - Inflammation and Cancer: Tumor Initiation and Progression / Metastasis Section 36	
3444 (Poster Board 7) - Characterization of immune environment in SV40C3-tag mouse model of triple-negative breast progression	J. Sandhu
3446 (Poster Board 9) - Acinar to ductal metaplasia is an evolutionary dead end and does not actively contribute to pancreas regeneration after damage	R. Shah
PO.MCB08.01 - Functional Genomics / Large-Scale Approaches to Cancer Gene Discovery Section 11	
2774 (Poster Board 12) - Pan-cancer chromatin state profiling suggests enhancer-heterogeneity and precision medicine approach	K. Rai
PO.TB05.01 - Developmental Origins and Drivers of Pediatric Cancers Section 4	
2627 (Poster Board 30) - Integrated multi-omics analyses discovers lineage plasticity in desmoplastic small round cell tumors	D. Truong
PO.TB09.02 - Microenvironment-Driven Cancer Evolution Section 6	
2676 (Poster Board 14) - Single cell spatial profiling reveals ERBB2 and EGFR co-expression in primary esophageal adenocarcinoma and brain metastasis tumors	N. Lawson
PO.TB10.03 - Aging and Senescence in the Tumor Microenvironment Section 2	
2561 (Poster Board 15)- Immune mediated expansion of p53 mutant clonal hematopoiesis following carboplatin treatment	R. Pourebrahim
PO.TB10.08 - Targeting the Tumor Microenvironment: A Brave New World Section 7	
2687 (Poster Board 4) - Exploring the synergistic mechanisms of VEGFR and immune checkpoint inhibitors in clear cell renal cell carcinoma metastases	A. Maksimovic
Tuesday, April 29	
9 a.m.-noon	
Posters Halls A, C, and F	
LBPO.ET03 - Late-Breaking Research: Experimental and Molecular Therapeutics 3 Section 52	
LB290 (Poster Board 13) - Identifying novel mechanisms of resistance to KRAS-inhibitors in NSCLC	S. Kundu
PO.BCS01.03 - Sequence Analysis and Genome Landscapes Section 46	
5037 (Poster Board 8) - Accelerated somatic mutation calling for whole-exome sequencing of tumor samples	J. Lal
5050 (Poster Board 21) - Comparative analysis of somatic copy number variations and allelic imbalance in whole-genome bisulfite sequencing: challenges and insights	Y. Gu
PO.CH01.01 - Computational Drug Discovery, Nanotechnology, and Therapeutics Section 25	
4460 (Poster Board 2) - OpencanSARchem: chemistry registration and standardization pipeline for FAIR integration of bioassay data	R. Chitsazi
4473 (Poster Board 15) - Liposomal nanoparticle mediated gene modulation for the treatment of melanoma in murine models	P. Yadav
PO.CH02.02 - Proteomic Biomarkers and Therapeutics Section 26	
4503 (Poster Board 14) - Analyzing and expanding the druggable proteome from predicted models	P. Gingrich
PO.CL01.10 - Predictive Biomarkers 5 Section 31	

4613 (Poster Board 3) - Differential TROP2 immunohistochemical expression between pleomorphic and classic invasive lobular carcinoma of the breast	E. Barrientos-Toro
PO.CL06.03 - Immune Responses to Therapies Including Chemotherapy and Radiotherapy Section 28	
4535 (Poster Board 6) - Targeting YAP1 and DKK1 pathways to suppress peritoneal carcinomatosis in gastric adenocarcinoma	Y. Fan
4543 (Poster Board 14) - Low dose radiation enhanced antitumor immune response by reprogramming T cell and CAR-T cell metabolism in a tumor immune microenvironment	Z. Rafiq
PO.CL13.01 - Molecular Diagnosis, Molecular Characterization and Theranostics of Tumors Section 30	
4594 (Poster Board 14) - EGFR PACC mutations occur more frequently as compound mutations with better responses to EGFR TKIs	X. Liu
PO.CT01.02 - First-in-Human Phase I Clinical Trials 2 Section 48	
CT143 (Poster Board 9) - First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Correlative data	M. Muftuoglu
CT154 (Poster Board 20) - BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study	E. Dumbrava
PO.CTP01.02 - Phase I Clinical Trials in Progress 2 Section 50	
CT200 (Poster Board 17) - Safety and efficacy of HLA-G-targeted CAR T cells (IVS-3001) in patients with advanced HLA-G-positive solid tumors: Clinical trial in progress	S. Srour
PO.EN01.01 - Molecular, Preclinical, and Clinical Endocrinology Section 35	
4756 (Poster Board 23) - Novel anaplastic thyroid carcinoma patient-derived xenograft models and cell line	A. Abubaker
PO.ET01.05 - Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 1 Section 19	
4306 (Poster Board 2) - KMT2A rearranged acute myeloid leukemia is vulnerable to the combinatorial inhibition of menin and MYC protein degradation	S. Nair
4317 (Poster Board 13) - Targeting KRAS in appendiceal cancer: promising results with MRTX1133 and RMC-6236 in organoids and PDX models	S. Chowdhury
PO.ET03.04 - Reversal of Drug Resistance 2 Section 23	
4440 (Poster Board 11) - The efficacy of NST-628, a non-degrading pan-RAF/MEK molecular glue, and MEK inhibitors for overcoming acquired osimertinib resistance mediated by TRIM24-BRAF fusions in EGFR mutant NSCLC	A. Guimaraes Paula
PO.ET06.07 - DNA Damage Response and Modulation of DNA Repair 2 Section 15	
4209 (Poster Board 26) - Targeting RNase H2: a dual mechanism strategy to elevate replication stress, DNA damage, and antitumor immunity in triple-negative breast cancer	T. Nguyen
PO.ET07.01 - Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics Section 20	
4352 (Poster Board 17) - Safety and pharmacokinetics of tinengotinib monotherapy in different doses and dosing schedules in advanced solid tumors	S. Piha-Paul
PO.IM02.04 - Epigenetic Regulation of Tumor Immunity Section 38	
4832 (Poster Board 2) - Differential roles of histone lactylation in regulating CD8 T cell effector functions and exhaustion	D. Raychaudhuri
4834 (Poster Board 4) - Genomic and metabolic effects of KDM6A loss regulates differential responses to immune checkpoint therapy and chemotherapy in bladder cancer	P. Singh
PO.MCB06.03 - Integrating Chromatin, Oncogenes, DNA Repair, and Biomarkers for Therapeutic Advancements Section 11	
4095 (Poster Board 2) - Advancing cancer prognosis: FFPE-CUTAC for comprehensive and affordable transcription profiling in oncology	Y. Zheng
PO.MCB07.01 - Gene Regulation and Transcription Factors 1 Section 9	
4045 (Poster Board 11) - Leiomyosarcoma is characterized by two distinct subtypes driven by NF1 or AP1 transcription factors	R. Denu
PO.MCB08.02 - High-Throughput Sequencing / Microarrays / Next-Generation Sequencing Section 10	
408 (Poster Board 18) - Analysis of low-grade serous ovarian cancer by long-read full length transcripts sequencing	K. Wong
PO.PR01.01 - Health Disparities across the Cancer Continuum Section 43	

4981 (Poster Board 28) - Implementation of a community-based HPV vaccination intervention supported by a cross-sector community coalition	R. Rechis
PO.TB04.01 - Mouse and Other Models Section 4	
3921 (Poster Board 14) - Development of a KRAS-G12C-driven pancreatic cancer mouse model	Y. Wei
PO.TB09.03 - Cancer Cell Heterogeneity, Evolution, and Trajectory Profiling Section 3	
3888 (Poster Board 12) - Exploring intra-tumor heterogeneity in malignant peripheral nerve sheath tumors through single-cell multi-omics	Y. Pan
3900 (Poster Board 24) - Integrating single-molecule localization microscopy and computational pipelines to elucidate ecDNA dynamics	M. Unal
PO.TB10.12 - The Tumor Immune Interplay as a Driver of Progression Section 6	
3962 (Poster Board 6) - Pan-cancer spatial characterization of tertiary lymphoid structures	K. Cho
3971 (Poster Board 15) - Single-cell transcriptomic insights into tumor and immune dynamics driving resistance to sitravatinib, nivolumab, and ipilimumab in advanced clear cell renal cell carcinoma	K. Yu
2-5 p.m.	Posters Halls A, C, and F
LBPO.IM03 - Late-Breaking Research: Immunology 3	
LB385 (Poster Board 7) - Immunomodulatory role of MUC5AC in lung adenocarcinoma: A potential therapeutic target	N. Karimi
LBPO.CL03 - Late-Breaking Research: Clinical Research 3 Section 53	
LB369 (Poster Board 13) - Final results of a phase I trial of evorpaccept (ALX148), lenalidomide, and rituximab for patients with B-cell non-Hodgkin lymphoma	T. Zhuang
LBPO.BCS02 - Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2 Section 52	
LB347 (Poster Board 10) - Telomere-to-telomere long read whole genome sequencing provides novel insights into ovarian cancer genomics	S. Takamatsu
PO.BCS01.07 - Computational Immunology and Tumor Microenvironment Characterization Section 45	
6270 (Poster Board 17) - AI-derived tumor-infiltrating lymphocytes predicts risk of invasive breast cancer recurrence in ductal carcinoma in situ (DCIS)	S. Ranjbar
PO.BCS01.11 - New Software Tools and Machine Learning Methods Section 46	
6303 (Poster Board 17) - DrBioRight: an AI-driven chatbot for cancer data analysis	H. Liang
6309 (Poster Board 23) - CliPP-on-Web: a dynamic platform for clonal structure identification through penalizing pairwise differences in cancers	A. Wu
PO.BCS02.04 - Computational and Systems Biology Approaches Section 44	
6246 (Poster Board 10) - Graph-based integration of multi-modal data uncovers cell-type specific vulnerabilities and advances toward a multi-scale digital twin	Y. Zhu
PO.CL06.10 - Immune Response to Therapies Section 28	
5820 (Poster Board 29) - Spatial and cellular immune landscapes of non-small cell lung cancer in association with response to neoadjuvant chemoimmunotherapy	Z. Rahal
5821 (Poster Board 30) - Targeting adenosine receptor signaling enhances anti-PD-L1 therapy efficacy in MTAP-deficient urothelial cancer via reprogramming tumor-associated macrophages	Y. Mei
PO.CL06.11 - Immunomodulatory Agents and Interventions Section 29	
5841 (Poster Board 17) - SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade	A. Grippin
5843 (Poster Board 19) - Selective small molecule inhibitor of STAT3 suppresses tumor growth and improves immune checkpoint inhibitor efficacy in KRAS mutant lung cancer	S. Deng
PO.CL10.03 - Real-World Data and Real-World Evidence: Clinical Informatics and Data Science 2 Section 33	
5952 (Poster Board 12) - Modulating treatment outcomes of patients with solid tumors in immunotherapy trials: a drug interaction analysis from a phase I unit	C. Braganca Xavier
PO.CT02.02 - Phase II Clinical Trials 2 Section 50	

CT209 (Poster Board 1) - Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C and STK11 mutations: KRYSTAL-1 phase 2 cohort	M. Negrao
PO.CTP02.01 - Phase II and Phase III Clinical Trials in Progress Section 51	
CT235 (Poster Board 4) - REPlot Trial: Phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4/6 inhibition	J. Mouabbi
CT243 (Poster Board 12) - Phase 2 study of Ivonescimab in patients with cutaneous squamous cell carcinoma	N. Akhave
CT245 (Poster Board 14) - Neoadjuvant immune checkpoint blockade + a prebiotic food-enriched dietary intervention to optimize immune response in melanoma: NEO-PreFED	Y. Jiang
CT246 (Poster Board 15) - Tagraxofusp plus venetoclax and azacitidine in patients ineligible for intensive chemotherapy with previously untreated CD123+ acute myeloid leukemia: A phase 2 multicenter trial	N. Daver
CT249 (Poster Board 18) - An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2	F. Meric-Bernstam
CT251 (Poster Board 20) - Phase 3 INTERpath-009 study: Individualized neoantigen therapy V940 (mRNA-4157) plus pembrolizumab for resected stage II-IIIb (N2) NSCLC with incomplete pathological response to neoadjuvant immunochemotherapy	T. Cascone
PO.ET03.07 - Drug Resistance in Molecular Targeted Therapies 3 Section 17	
5517 (Poster Board 12) - Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy	I. Meraz
5529 (Poster Board 24) - Development and characterization of BRAF/MEK inhibitor resistant anaplastic thyroid carcinoma patient-derived xenograft and cell line models	A. Abubaker
PO.ET09.14 - Novel Antitumor Agents 3 Section 21	
5625 (Poster Board 3) - EphB4 agonist B4-007 was effectively against high-grade serous ovarian cancer (HGSC) as a single agent in cell-based and patient-derived xenograft models	Q. Teng
PO.IM01.04 - CAR Therapies: Emerging Approaches and Combinations Section 38	
6112 (Poster Board 20) - Supercharging anti-tumor immunity in hepatocellular carcinoma with PH102: A CAR T-cell-based platform	V. Pham
PO.IM01.16 - Interplay between Immune System and Radio-, Chemo- and Targeted Therapies 2 Section 40	
6154 (Poster Board 6) - Diffusing alpha-emitters radiation therapy in combination with anti-CTLA-4, as well as combination with both ATR inhibitor, and anti-CTLA-4 achieves long-lasting tumor regression in murine pancreatic cancer	M. Reis
PO.MCB08.03 - Genomic Profiling of Tumors 1 Section 11	
5347 (Poster Board 1) - Transcriptome analysis for Merkel cell carcinoma patients testing positive (+) and negative (-) for polyomavirus	M. Pérez Salvá
PO.MCB09.05 - Therapeutic Targets and Mitochondrial Function Section 14	
5426 (Poster Board 4) - Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer	M. Zuo
PO.PR02.01 - Development of Chemopreventive Agents and Preclinical Models Section 48	
6332 (Poster Board 13) - Targeting PARP for the prevention of BRCA1-deficient triple-negative breast cancers	A. Lanier
PO.TB04.07 - Mouse Models of Cancer and Mechanisms Section 3	
5167 (Poster Board 15) - Development of advanced preclinical models for an in-depth characterization of cardiac angiosarcoma	R. Minelli
PO.TB08.01 - Tumor Microenvironment and Metastasis Section 7	
5280 (Poster Board 8) - A strategic framework for modeling abnormal quiescence that drives cancer evolution, and for preclinical development of therapies to prevent recurrence and metastasis in high-risk patients	B. Singh
PO.TB10.01 - A Role for the Tumor Microenvironment in Progression Section 1	

5107 (Poster Board 12) - Alterations in cancer-associated fibroblasts are associated with a dysfunctional T cell phenotype and antioxidant response in LKB1/KEAP1-mutant lung adenocarcinoma	A. Karimi
PO.TB10.06 - Where's Waldo: Spatial Complexity of the Tumor Microenvironment 2 Section 8	
5305 (Poster Board 11) - Tumor cell lineages and immune remodeling of RHOA Y42C-driven diffuse gastric cancer	K. Ko
5323 (Poster Board 29) - Spatial heterogeneity of tumor and stromal cells in desmoplastic small round cell tumors	J. Fan
PO.TB10.09 - The Immune Microenvironment in Cancer Section 6	
5246 (Poster Board 6) - Chromosomal instability promotes colorectal cancer progression through manipulation of gamma delta T cells	P. Tallón de Lara
5268 (Poster Board 28) - Impede cancer brain metastasis by enhancing innate immunity with CCL2 targeting	Y. Duan
Wednesday, April 30	
9 a.m.-noon	
LBPO.CL04 - Late-Breaking Research: Clinical Research 4 Section 49	
LB414 (Poster Board 20) - Characterization of the genomic landscape of BRAF-, RAS-, and fusion-negative thyroid carcinomas underscores the role of tumor suppressor genes	V. Rodrigues Marczyk
PO.BCS01.10 - Tumor Evolution, Clonal Progression, and Spatiotemporal Dynamics Section 46	
7490 (Poster Board 3) - Uncovering rare cellular populations in esophageal preneoplasia through genetic perturbation tracking and scRNA-seq	J. Jang
7492 (Poster Board 5) - "Baseline-informed" unsupervised multiplexed CyTOF analysis enhances detection of minimal/measurable residual disease in acute myeloid leukemia	M. Basyal
7499 (Poster Board 12) - Driver mutations propel subclonal evolution and spatial patterns of tumor growth in intrahepatic cholangiocarcinoma	E. John
7501 (Poster Board 14) - APOBEC3A drives chromosomal instability and tumor evolution in pancreatic cancer	Z. Zhang
7509 (Poster Board 22) - Path-Omics: Elevated plasma cell infiltration into aneuploid epithelium predicts Barrett's esophagus progression to adenocarcinoma	X. Pan
PO.BCS02.03 - Identification of New Cancer Vulnerabilities Through Convergence Science Section 45	
7461 (Poster Board 6) - Identifying molecular vulnerabilities in rare cancers using a novel graph-based therapeutic discovery model	L. Zhao
7475 (Poster Board 20) - A comprehensive single-cell atlas of gastric cancer reveals malignant cell state dynamics and plasticity in tumor progression and metastasis	E. Dai
PO.CL01.06 - Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1 Section 32	
7153 (Poster Board 17) - Subclonal mutation load predicts survival and response to immunotherapy in cancers with low to moderate TMB	M. Montierth
7166 (Poster Board 30) - Spatially resolved protein profiling of tumor and immune microenvironment in EGFR mutant NSCLC with transformation to SCLC	H. Chen
PO.CL06.09 - Immune Monitoring / Clinical Correlate Section 31	
7124 (Poster Board 3) - Imaging mass cytometry (IMC) reveals distinct intratumoral B and T regulatory cell populations in responder versus non-responder soft tissue sarcoma (STS) patients before treatment with immune checkpoint blockade (ICB)	M. Chelvanambi
PO.CL07.02 - Advances in Translational Pediatric Cancer Research Section 28	
7036 (Poster Board 6) - Co-targeting AR, mTOR, and PI3K inhibitors in DSRCT as a novel therapeutic approach	R. Cardenas-Zuniga
PO.CL08.04 - Targeted Therapies and Combinations 4 Section 35	
7220 (Poster Board 26) - Zongertinib demonstrates potent efficacy against cancer cells harboring HER2 non-tyrosine kinase domain mutations	Y. Shibata
PO.CL13.03 - Molecular Genetics and Epigenetics of Tumors Section 34	
7175 (Poster Board 6) - STAT3/STAT5 mutation predicts shorter overall survival in patients with plasma cell myeloma	M. Ye

PO.ET02.13 - Antibody-Based Cancer Therapeutics 4 Section 16	
6740 (Poster Board 6) - Dual targeting of amyloid precursor protein with α -secretase inhibitor and antibody-drug conjugate synergistically reduces tumor progression in colorectal cancer	R. Dou
PO.ET03.09 - Drug Resistance in Molecular Targeted Therapies 5 Section 18	
6795 (Poster Board 7) - Cystine deprivation overcomes protective effects of hypoxia on ferroptosis in high-grade serous ovarian cancer	Z. Tang
PO.ET07.02 - Mechanisms of Cancer Therapeutics Section 19	
6825 (Poster Board 10) - Novel therapeutic strategies targeting MECOM rearranged AMLs discovered by unbiased drug screen	C. Birdwell
PO.IM01.09 - Overcoming Checkpoint Inhibition and Tumor Suppression Section 39	
7304 (Poster Board 19) - Cytotoxic PD-L1/PD-L2 dual-specific antibodies couple tumor stroma remodeling with checkpoint blockade to drive rejection of "cold" cancers	M. Curran
7311 (Poster Board 26) - Targeting STAT3 to prevent non-small cell lung cancer in patients with chronic obstructive pulmonary disease	K. Larsen
PO.IM01.17 - Novel In Vivo, In Vitro, and In Silico Models Section 38	
7271 (Poster Board 18) - SENTI-202 CD33 OR FLT3 NOT EMCN logic-gated gene circuit components selectively target AML while protecting human HSC/HPCs from off-tumor toxicity in a humanized mouse model	M. Muftuoglu
PO.IM02.07 - Novel Animal Models / Tumor Antigenicity/Processing and Presentation Section 37	
7226 (Poster Board 2) - Development of syngeneic tobacco associated oral cancer models using Trp53 and Cdkn2a mutant mice	R. Rangel
PO.MCB08.05 - Genomic Profiling of Tumors 3 Section 10	
6620 (Poster Board 1) - Low interferon expression coupled with 9p21 loss in non-small cell lung cancer (NSCLC) patients associated with distinct somatic landscape, altered immune population, and poorer response to immune checkpoint inhibitor (ICI) therapies	N. Vokes
PO.MCB09.03 - Metabolism and Signaling Section 11	
6659 (Poster Board 14) - Defective lipid homeostasis induced by QKI loss is a mutator on gliomagenesis	Y. Guan
PO.PS01.09 - Innovations in Prevention and Cancer Care: Addressing Disparities, Inflammation, Survivorship, and Modifiable Risk Factors Section 41	
7363 (Poster Board 21) - Providers' beliefs, perceived skill, and perception of organizational norms relate to their delivery of cigarette smoking intervention to patients seen in healthcare centers serving rural and medically underserved areas of Texas	A. Siddiqi
PO.TB10.02 - Our Commensal Tumor Microenvironment and Its Role in Cancer Section 4	
6520 (Poster Board 6) - Intratumoral microbiome profiling using high-depth whole-genome sequencing highlighted Cutibacterium acnes in chemoresistance in ovarian cancer	S. Lee
PO.TB10.04 - Vesicles in the Tumor Microenvironment Section 6	
6583 (Poster Board 23) - Optimized production, biodistribution, and targeted delivery of T cell-derived extracellular vesicles for liver cancer therapy	A. Jaffery